Octagon Therapeutics
octagontherapeutics.comOctagon targets autoimmune and inflammatory diseases including systemic lupus erythematosus, multiple sclerosis, Sjögren's, myositis, and metabolic/inflammatory conditions. They utilize a proprietary glycoproteome discovery platform to identify disease-driving biology and develop selective immune checkpoint modulators.
Check Size
Not specified
Stages
Not specified
Focus Areas
Not specified
Is Octagon Therapeutics right for your startup?
Upload your pitch deck and get an AI-powered match score in minutes. See exactly how well you fit their investment criteria.
See If You're a MatchInvestment Thesis
Octagon Therapeutics is focused on discovering and developing medicines for patients with autoimmune and inflammatory diseases by leveraging proprietary insights into the glycoproteome. The company believes that patients with severe autoimmunity deserve treatment options that preserve healthy immune functioning, rather than broadly suppressing the immune system. Their approach centers on restoring the activity of disrupted immune checkpoint receptors to restore healthy immune homeostasis.
What Sets Them Apart
- Proprietary Glycoproteome Discovery Engine that leverages glycobiology insights - glycans increase proteome diversity by orders of magnitude and affect protein receptor binding, enzymatic processing, and stability
- Focus on selective immune checkpoint restoration rather than broad immunosuppression, specifically targeting autoimmune checkpoints while preserving healthy immune function
- Ability to target disease-associated lymphocytes with high specificity - evidenced by partnership with Novo Nordisk for inflammatory disease targets
- Scientific foundation from Harvard with experienced team of scientists, clinicians, and entrepreneurs with decades of research experience
- Established partnerships with leading institutions including Slater Technology Fund, Novo Nordisk, and presence at The Engine in Cambridge
Ready to find your perfect investor match?
Get Started Free